Questcor Pharmaceuticals

Hayward, CA 94545

Market Performance

NASDAQ: QCOR
52 Week High $98
52 Week Low $59

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $373K
First Award Date 02/15/93
Most Recent Award Date 05/01/00

Key Personnel

Last Name Name Awards Contact
Marangos Paul J Marangos 5
Makings Lewis R Makings 1
Wiemann Torsten R Wiemann 1
Witherell Gary W Witherell 1

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/00 - 04/30/03

DESCRIPTION (Investigator's Abstract): One consequence of traumatic (head injury) and ischemic (stroke) brain injury that has been largely ignored in therapeutics development is glial swelling. Glial (astrocytic) swelling causes impingement on blood capillaries, reducing t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/21/99 - 04/30/00

DESCRIPTION (Investigator's Abstract): One consequence of traumatic (head injury) and ischemic (stroke) brain injury that has been largely ignored in therapeutics development is glial swelling. Glial (astrocytic) swelling causes impingement on blood capillaries, reducing t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/10/98 - 09/30/98

DESCRIPTION: (Adapted from the applicant's abstract) Cardiovascular and central nervous system ischemia are major medical problems which remain largely untreatable. Therapies targeting (I) adenosine, a known cytoprotective compound during conditions of ischemia, and (ii) oxygen- derived free radicals h...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/97 - 08/31/98

DESCRIPTION (Investigator's Abstract): One consequence of traumatic (head injury) and ischemic (stroke) brain injury that has been largely ignored in therapeutics development is glial swelling. Glial (astrocytic) swelling causes impingement on blood capillaries, reducing t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/96 - 11/30/96

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/95 - 08/31/96

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/94 - 08/31/95

The primary goal of this proposal is to develop a new class of calcium channel blocker that will act specifically at the neuronal N-type calcium channel. Agents that specifically block this channel are expected to inhibit the excessive release of various neurotransmitters which cause cell damage after ischemia. Two classes of lead molecules who...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/15/93 - 08/14/93

There are currently no treatments for the neurodegeneration that occurs following a stroke or head trauma. Recent breakthroughs in understanding of the mechanisms by which nervous tissue degenerates have made it possible to design therapeutic drug strategies to prevent the process. NeuroTherapeutics Corporation seeks to develop rational drug tr...